A professional analysis of the potential cost-effective impact of emerging dry eye therapies on the health care system.
This is a video synopsis/summary of a Stakeholder Summit involving:
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.
Haumschild queries cost-effectiveness considerations around emerging dry eye disease (DED) therapies. Parekh states early DED identification and tailored treatment represents prevention, optimizing societal outcomes over following thousands of patients. Applying this population health approach can modify disease trajectory. Delaying intervention risks irreversible ocular surface damage and vision impairment despite eventual treatment. An upfront focus on appropriate therapy facilitates quality outcomes in a value-based model.
Kabiri discusses the responsibility for providers to address DED’s high prevalence with patient education and evidence-based recommendations, not just reacting to active complaints. Patients increasingly self-diagnose DED and expect specialist guidance on best practices. Effectively communicating around promising therapies enables access that impacts countless patients. Haumschild concurs this represents both an obligation and opportunity for optimal DED management benefiting all stakeholders.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More